Showing Results for: “exercise”

In an analysis of the AWARD-7 study, people with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD) who took 1.5 mg of dulaglutide once weekly had a reduction of clinical events associated with end-stage kidney disease (ESKD) including dialysis and with a kidney transplant, and a slower rate of kidney function decline compared to people who used insulin or a lower dose of dulaglutide. The study is an abstract titled “Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) Versus Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria

Children with early-onset type 1 diabetes (T1D) and poor glycemic control have slower growth of areas in the brain associated with mild cognitive deficits compared to children without diabetes, according to the study, “ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet),” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study found that children with early-onset T1D have mild but

Top researchers, clinicians and educators will be recognized at the 79th Scientific Sessions for outstanding leadership and work to advance diabetes research, prevention, care and treatment The American Diabetes Association (ADA) is proud to announce the recipients of the ADA’s 2019 National Scientific and Health Care Achievement Awards. Individually and collectively, their exemplary leadership, mentorship and many achievements have advanced the field of diabetes care and improved health outcomes for people living with diabetes. “This year’s National Scientific and Health Care Achievement

Results of NIDDK’s, Fuzzy Logic Automated Insulin Regulation (FLAIR) study showed increased time in range and improved A1C levels in adolescents and young adults who used system Medtronic’s Advanced Hybrid Closed-Loop system use in adolescents and young adults with type 1 diabetes (T1D) can lead to improved daytime blood sugar control without an increase in hypoglycemia, according to research presented today at the American Diabetes Association’s® (ADA’s) 80th Scientific Sessions. The presentation, “FLAIR—An NIDDK-Sponsored International, Multi-site Randomized Crossover Trial of AHCL vs. 670G

Learn what is, causes of insulin resistance, what does it mean for your health, treatment and what you can do about preventing or reversing the conditions.

With the help of your health care team, you can find an insulin routine that will keep your blood glucose (blood sugar) near normal, help you feel good, and fit your lifestyle.

Resources, stories, and support for families navigating diabetes in childhood and adolescence together.

The Teplizumab Prevention Trial has given validity to the concept that immune therapy can delay the diagnosis of type 1 diabetes (T1D), according to findings presented at a symposium entitled “New Therapeutic Approaches and Insights for Type 1 Diabetes” today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Family members of someone with T1D have a 15 times greater risk of developing T1D than individuals from the general population. Testing can determine the presence of autoantibodies, indicating risk for T1D, and the

During National Influenza Vaccination Week, experts encourage everyone 6 months and older to get vaccinated to reduce risk of severe illness and hospitalization To kick off National Influenza Vaccination Week (December 1 - 6), the American Heart Association®, American Lung Association, American Diabetes Association® (ADA) and National Foundation for Infectious Diseases are urging everyone 6 months and older to get an annual flu vaccine. This year’s flu season follows a particularly difficult flu season. The 2024–2025 flu season was classified by the U.S. Centers for Disease Control and